Stay updated on Efficacy of Nivolumab and Ipilimumab in Esophageal Cancer Clinical Trial
Sign up to get notified when there's something new on the Efficacy of Nivolumab and Ipilimumab in Esophageal Cancer Clinical Trial page.

Latest updates to the Efficacy of Nivolumab and Ipilimumab in Esophageal Cancer Clinical Trial page
- Check2 days agoChange DetectedThe collaborator name has been updated to Ono Pharmaceutical Co., Ltd and the revision version changed from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check9 days agoChange DetectedPadua, Italy was replaced with Padova, Italy in the study locations list (local name Padova).SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedPage version updated from v3.4.3 to v3.5.0. This appears to be a technical update that does not change trial details or results.SummaryDifference0.0%

- Check38 days agoChange DetectedThe page now shows Revision: v3.4.3 and no longer lists Revision: v3.4.2.SummaryDifference0.0%

- Check59 days agoChange DetectedThe study locations have been expanded with multiple new sites worldwide, and the follow-up periods for overall survival and progression-free survival have been extended to up to 88 months, with several previously listed sites and shorter timeframes removed.SummaryDifference2%

- Check67 days agoChange DetectedA new revision tag, Revision: v3.4.2, was added to the page; the previous maintenance notice about a lapse in government funding and the Revision: v3.4.1 tag were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Efficacy of Nivolumab and Ipilimumab in Esophageal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy of Nivolumab and Ipilimumab in Esophageal Cancer Clinical Trial page.